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Abstract
Background: Certain endogenous metabolites can influence the rate of cancer cell growth. For
example, diacylglycerol, ceramides and sphingosine, NAD+ and arginine exert this effect by acting
as signaling molecules, while carrying out other important cellular functions. Metabolites can also
be involved in the control of cell proliferation by directly regulating gene expression in ways that
are signaling pathway-independent, e.g. by direct activation of transcription factors or by inducing
epigenetic processes. The fact that metabolites can affect the cancer process on so many levels
suggests that the change in concentration of some metabolites that occurs in cancer cells could
have an active role in the progress of the disease.
Results: CoMet, a fully automated Computational Metabolomics method to predict changes in
metabolite levels in cancer cells compared to normal references has been developed and applied
to Jurkat T leukemia cells with the goal of testing the following hypothesis: Up or down regulation in
cancer cells of the expression of genes encoding for metabolic enzymes leads to changes in intracellular
metabolite concentrations that contribute to disease progression. All nine metabolites predicted to be
lowered in Jurkat cells with respect to lymphoblasts that were examined (riboflavin, tryptamine, 3-
sulfino-L-alanine, menaquinone, dehydroepiandrosterone, α-hydroxystearic acid, hydroxyacetone,
seleno-L-methionine and 5,6-dimethylbenzimidazole), exhibited antiproliferative activity that has
not been reported before, while only two (bilirubin and androsterone) of the eleven tested
metabolites predicted to be increased or unchanged in Jurkat cells displayed significant
antiproliferative activity.
Conclusion: These results: a) demonstrate that CoMet is a valuable method to identify potential
compounds for experimental validation, b) indicate that cancer cell metabolism may be regulated
to reduce the intracellular concentration of certain antiproliferative metabolites, leading to
uninhibited cellular growth and c) suggest that many other endogenous metabolites with important
roles in carcinogenesis are awaiting discovery.
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Background
Elucidating the metabolic changes exhibited by cancer
cells is important not only for diagnostic purposes, but
also to more deeply understand the molecular basis of car-
cinogenesis, which could lead to novel therapeutic
approaches. By regulating the expression of oncogenes or
modulating various signal transduction systems, it is
widely accepted that certain metabolic processes play fun-
damental roles in cancer progression. The significance of
other metabolic phenotypes observed in cancer is more
controversial, e.g. the shift in energy production from oxi-
dative phosphorylation (respiration) to aerobic glycolysis
known as the Warburg effect [1]. The mainstream view
has been that the Warburg effect is a consequence of the
cancer process (secondary events due to hypoxic tumor
conditions) rather than a mechanistic determinant, as
originally hypothesized. Recently, however, a different
picture of the role of metabolic changes in tumorigenesis
has emerged; for example, the dichloroacetate-induced
reversion from a cytoplasm-based glycolysis to a mito-
chondria-located glucose oxidation inhibits cancer
growth, supporting the idea that the glycolytic shift is a
fundamental requirement for cancer progression [2] and
opening up the possibility of targeting metabolic path-
ways for cancer treatment [3].
Changes in intracellular concentrations of certain metab-
olites can influence the rate of cancer cell growth. A
metabolite can exert this effect by acting as a signaling
molecule, a role that does not preclude other important
cellular functions. For instance, diacylglycerol, a lipid that
confers specific structural and dynamic properties to bio-
logical membranes and serves as a building block for
more complex lipids is also an essential second messenger
in mammalian cells whose dysregulation contributes to
cancer progression [4]. Similarly, structural components
of cell membranes such as ceramides and sphingosine are
also second messengers with antagonizing roles in cell
proliferation and apoptosis [5]. Pyridine nucleotides con-
stitute yet another example, having well characterized
functions as electron carriers in metabolic redox reactions
and roles in signaling pathways [6]. In particular, NAD+
modulates the activity of sirtuins, a recently discovered
family of histone deacetylases [7] that may contribute to
breast cancer tumorigenesis [8]. Arginine is yet another
metabolite involved in numerous biosynthetic pathways
that also has a fundamental role in tumor development,
apoptosis and angiogenesis [9]. Considering that the sig-
naling role of many of these biomolecules was not even
suspected a decade ago, it is likely that the role of other
metabolites as second messengers will be discovered.
It is becoming increasingly clear that cellular metabolites
can also be involved in the control of cell proliferation by
directly regulating gene expression. Signaling pathway-
independent modulation of gene expression by metabo-
lites can occur on three levels [10]: First, metabolites can
bind to regulatory regions of certain mRNAs (ribos-
witches), inducing allosteric changes that regulate the
transcription or translation of the RNA transcript; how-
ever, this type of direct metabolite-RNA interaction has
not yet been detected in humans [11]. Second, transcrip-
tion factors can be activated upon metabolite binding, e.g.
binding of steroid hormones to the estrogen receptor tran-
scription factor induces gene expression events leading to
breast cancer progression [12]. Third, metabolites can be
involved in epigenetic processes such as post-translational
modification of histones that regulate gene expression by
changing chromatin structure [13]. The modulation of the
rate of histone acetylation by nuclear levels of acetyl-CoA
is an example of metabolic control over chromatin struc-
ture that involves epigenetic changes linked to cell prolif-
eration and carcinogenesis [14].
The fact that metabolites can affect the cancer process on
so many levels suggests that the manipulation of specific
metabolic pathways may offer a reasonable therapeutic
approach. In fact, this is the basis of several anticancer
therapies that: i) have been proposed based on experi-
mental evidence, ii) are currently the object of validation
in clinical trials, or iii) are presently in clinical use. The
inactivation of the metabolic enzymes KIAA1363 [15] and
indoleamine 2,3-dioxygenase [16] constitutes a good
example of i). As for ii), several anticancer treatments that
exploit the antiproliferative action of ceramide are exam-
ples of therapies based on the pharmacological manipula-
tion of a metabolic pathway that are currently in clinical
trials [5]. Turning to iii), a metabolite-based therapy for
acute lymphoblastic leukemia used since 1970 [17] con-
sists of depleting circulating asparagine by administration
of the bacterial enzyme L-asparaginase.
The analysis of metabolic features associated with neu-
roendocrine cancers by a combination of experimental
techniques (magic angle spinning NMR spectroscopy and
microanalytical biochemical assays) and in silico methods
(reconstruction of metabolic pathways from microarray
gene expression data and predictions of possible biotrans-
formations based on the chemical groups present in a
given metabolite) have resulted in a promising metabo-
lome-directed therapy [18]. The goal is the detection of
unusual pathways in the reconstructed metabolism of the
cancer cell whose components can be targeted by already
available drugs. In general, preventive and therapeutic
anticancer approaches based on the pharmacological
manipulation of metabolism aim to increase or decrease
the intracellular levels of certain metabolites by adminis-
tration of either the metabolites themselves, inhibitors/
activators of relevant enzymes, or inhibitors/activators of
specific transporters.Molecular Cancer 2008, 7:57 http://www.molecular-cancer.com/content/7/1/57
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In this study, we hypothesize that the change in concen-
tration of some metabolites that occurs in cancer cells
could have an active role in the progress of the disease
rather than merely being an inconsequential side effect.
We explore whether the reversion to a metabolic pheno-
type more similar to the normal state might be of possible
therapeutic value. Increasing the levels of certain com-
pounds that are lowered in cancer cells could be straight-
forwardly achieved by directly administering the deficient
metabolite. On the other hand, for metabolites whose lev-
els are increased in cancer cells, reversion would involve
activation or inhibition of key enzymes, an approach that
is more difficult to implement. For that reason, here we
decided to focus on the former case. Ideally, we would like
to compare the actual intracellular levels of every human
metabolite in normal and diseased states to identify those
that are lowered in cancer cells. However, direct large-
scale biochemical assays are currently unfeasible. Metabo-
lite profiling based on NMR [19] or mass spectrometry
techniques [20], although very powerful, require costly
instruments and are not free of problems and limitations.
In silico methods based on linking enzymes to upregulated
microarray-detected transcripts and mapping to meta-
bolic pathways have been applied to the qualitative recon-
struction of the metabolome of cancer cells and some
predictions have been successfully validated by biochem-
ical experiments [18]. Here, we describe CoMet, a fully
automated and general Computational Metabolomics
method that uses a Systems Biology approach to predict
the human metabolites whose intracellular levels are
more likely to be altered in cancer cells. We then prioritize
the metabolites predicted to be lowered in cancer com-
pared to normal cells as potential anticancer agents. We
applied our methodology to a leukemia cell line and dis-
covered several human metabolites that either alone or in
combination, exhibit various degrees of antiproliferative
activity.
Results
Computational Metabolomics of Jurkat T cell line
The basic idea behind CoMet is schematically described in
Figure 1. The intracellular level of a given metabolite is
predicted to be decreased or increased in cancer cells
based on the analysis of the relative expression levels of
the human genes encoding for all identified enzymes that
employ the metabolite as substrate or product (see Mate-
rial and Methods for details). We applied our approach to
the Jurkat cell line, which is derived from an acute T lym-
phoblastic leukemia patient [21]. The comparison of two
Jurkat cell samples to three GM15851 lymphoblast cell
samples (see Additional File 1) resulted in 104 metabo-
lites predicted to be lowered in Jurkat cancer cells and 78
metabolites predicted to be increased in these cells, out of
a total of 982 metabolites considered in the analysis (see
Additional File 2). According to our hypothesis, we would
expect an enrichment of Jurkat antileukemic agents
among the 104 metabolites predicted to be lowered in the
cancer cells. By performing an exhaustive search of the lit-
erature for experimental evidence, we found that 13 of the
982 analyzed metabolites has previously been demon-
strated to exhibit anticancer activity in Jurkat cells. Table 1
shows that 2/13 metabolites are predicted to be lowered
in Jurkat cells: thymidine, an antineoplastic agent [22],
and prostaglandin D2, which induces apoptosis without
inhibiting the viability of normal T lymphocytes [23].
Only 1/13 proven anticancer agents in Jurkat cells belongs
to the group of 78 metabolites predicted to be increased
in these cancer cells: the apoptotic agent 17β-2-methox-
yestradiol [24]. The remaining 10 known anticancer mol-
ecules active in Jurkat cells: testosterone [25], melatonin
[26], sphingolipid GD3 [27], 2'-deoxyguanosine [28], 2'-
deoxyadenosine [29], 2'-deoxyinosine [29], nicotinamide
[30], methylglyoxal [31], linoleic acid [32] and cAMP [33]
are included in the set of 800 metabolites whose intracel-
lular levels are predicted to be essentially the same in both
Jurkat and normal cells. Although the fraction of metabo-
lites with known anticancer activity among the com-
pounds predicted to be lowered in Jurkat cells (2/104 =
0.019) is higher than that corresponding to the rest of the
compounds [11 non predicted ones have literature vali-
dated anticancer properties; (1+10)/(78+800) = 0.013],
the difference is not statistically significant (two-tailed
Fisher's exact test at a critical alpha level of 0.05). On the
other hand, it has to be noticed that negative results tend
to be underreported, making it difficult to obtain unbi-
ased statistics about metabolites that lack anticancer prop-
erties.
Tested metabolites predicted to be lowered in Jurkat cells 
are antiproliferative
Based on simple criteria such as low molecular weight,
commercial availability and affordability, we selected
nine metabolites predicted to be lowered in Jurkat cells in
order to test their effect on its proliferation (Table 1). For
one of these nine metabolites (seleno-L-methionine) we
carried out a validation by quantitative real-time PCR of
the microarray data used by CoMet to make its prediction
(see Additional File 3). We examined the effect on the
growth of Jurkat cells of a 72 h treatment with riboflavin,
tryptamine, 3-sulfino-L-alanine, menaquinone, dehy-
droepiandrosterone (the non-sulfated version of the pre-
dicted metabolite dehydroepiandrosterone sulfate), α-
hydroxystearic acid (one of the possible compounds com-
patible with the predicted generic metabolite α-hydroxy
fatty acid), hydroxyacetone, seleno-L-methionine and 5,6-
dimethylbenzimidazole (the aglycone of the predicted
metabolite α-ribazole) at a concentration of 100 μM (see
Additional File 1). Figure 2A shows that all the tested
metabolites with the exception of sulfino-L-alanine exhib-
ited statistically significant antiproliferative activity onMolecular Cancer 2008, 7:57 http://www.molecular-cancer.com/content/7/1/57
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Jurkat cells (as evaluated by two-tailed t-tests at a critical
alpha level of 0.05), with growth below 90% of the
untreated control in all the cases. Although sulfino-L-
alanine alone did not inhibit the growth of Jurkat cells, it
significantly potentiated the inhibitory effect of seleno-L-
methionine (43.1% to 30.3% growth compared to con-
trol). Similarly, a synergistic interaction between 5,6-
dimethylbenzimidazole and seleno-L-methionine led to a
supra-additive growth inhibitory activity. On the other
hand, α-hydroxystearic acid and dehydroepiandrosterone
show an additive effect, while α-hydroxystearic acid and
seleno-L-methionine exhibited sub-additive or antagonis-
tic inhibitory activity. Menaquinone showed the highest
antiproliferative activity (11.3% growth compared to con-
trol), whereas the inhibitory activity of riboflavin, tryp-
tamine and hydroxyacetone on Jurkat cells was more
moderate (all above 70% growth compared to control).
Thus, even with the small set tested, a remarkable richness
of antiproliferative responses is seen.
Most tested metabolites predicted to be augmented or 
unchanged in Jurkat cells are not antiproliferative
Although the fact that the nine tested metabolites pre-
dicted to be lowered in Jurkat cells exhibited antiprolifer-
ative activity strongly support our hypothesis, the
possibility still exists that many endogenous metabolites
at the concentration used in our test inhibit the growth of
Jurkat cells, independent of the intracellular level status
predicted by CoMet. Therefore, we tested metabolites
whose intracellular levels in Jurkat cells were predicted to
be increased (bilirubin, androsterone, homovanillic acid,
vanillylmandelic acid, N-acetyl-L-aspartate and tauro-
cholic acid) or unchanged (pantothenic acid, citric acid,
folic acid, β-D-galactose, cholesterol) compared with lym-
phoblasts. We analyzed the effect on the growth of Jurkat
cells of a 72 h treatment with each of the eleven human
metabolites at a concentration of 100 μM (see Additional
File 1). Figure 2B shows that only two of the six tested
metabolites whose concentrations are predicted to be
increased in Jurkat cells exhibit significant antiprolifera-
tive activity: bilirubin and androsterone (19.6% and
54.5% growth compared to control, respectively). The
growth inhibition exerted by each of the remaining tested
metabolites was less than 10% and statistically insignifi-
cant. Similarly, Figure 2C shows that all the tested metab-
olites whose intracellular levels in Jurkat cells and
lymphoblasts we predict to be comparable, exhibit no sig-
nificant effect on the growth of cells. Statistical signifi-
Table 1: Active metabolites predicted to be lowered in Jurkat 
cells
Previously known anticancer activity in Jurkat cells
thymidine (C00214)1
prostaglandin D2 (C00696)
Anticancer activity in Jurkat cells tested in this work
riboflavin (C00255)
tryptamine (C00398)
3-sulfino-L-alanine (C00606)
menaquinone (C00828)
dehydroepiandrosterone sulfate (C04555)
α-hydroxy fatty acid (C05102)
hydroxyacetone (C05235)
seleno-L-methionine (C05335)
α-ribazole (C05775)
1 KEGG ligand identifier
Diagram representing the rationale of CoMet Figure 1
Diagram representing the rationale of CoMet. (A) The 
intracellular level of a metabolite X is predicted to be 
increased in cancer cells when enzymes that produce X are 
upregulated and/or enzymes that consume X are downregu-
lated in cancer cells. (B) The intracellular level of a metabo-
lite X is predicted to be decreased in cancer cells when 
enzymes that produce X are downregulated and/or enzymes 
that consume X are upregulated in cancer cells. See Material 
and Methods for a complete description of the rules.
produce X
Reactions
consume X
Reactions
[X]
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D
E
X
X
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B
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A
Prediction
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cance was evaluated in all the cases according to two-
tailed t-tests at a critical alpha level of 0.05.
Predicted metabolites that are antiproliferative in Jurkat 
cells show lower or no activity in lymphoblasts
To validate the relevance of the identified antiproliferative
metabolites as potential anticancer agents, we investi-
gated the selectivity of their antiproliferative activity
towards Jurkat cells with respect to human lymphoblast
cells. We compared the effect of a 72 h treatment with
menaquinone, dehydroepiandrosterone, seleno-L-
methionine and 5,6-dimethylbenzimidazole at concen-
trations of 100 and 50 μM on the growth of Jurkat cells
and human GM15851 lymphoblast cells cultured in the
same conditions (see Additional File 1). Table 2 shows
that menaquinone and dehydroepiandrosterone at con-
centrations of 100 or 50 μM exhibit significant antiprolif-
erative activity on Jurkat cells but not on lymphoblast
cells. Moreover, dehydroepiandrosterone at a concentra-
tion of 50 μM shows a statistically significant stimulation
of the growth of lymphoblasts (130% growth compared
to control), while at the same concentration in Jurkat cells
the growth rate is reduced to 83.2%, thereby providing an
interesting example of selective inhibition. Seleno-L-
methionine inhibits the growth of Jurkat and lymphob-
last cells at both tested concentrations; however, the effect
on Jurkat cells was considerably more potent. While 5,6-
dimethylbenzimidazole at a concentration of 100 μM
exhibits significant antiproliferative activity on both
tested cell lines, at a concentration of 50 μM it only inhib-
its Jurkat cells. Statistical significance was evaluated in all
the cases according to two-tailed t-tests at a critical alpha
level of 0.05.
Discussion
Novel antiproliferative compounds discovered by CoMet
At a concentration of 100 μmol/L, all nine metabolites
predicted to be lowered in Jurkat cells selected for cell pro-
liferation assays exhibited a statistically significant inhibi-
tion of Jurkat cell growth below 90% of the untreated
control, whether alone, in most of the cases, or in combi-
nation, in the case of 3-sulfino-L-alanine (Figure 2A). On
the other hand, 2/6 tested metabolites predicted to be
increased in Jurkat cells unexpectedly exhibited antiprolif-
erative activity (Figure 2B), while none of the five tested
metabolites that we predicted to be unchanged inhibited
Jurkat cell growth (Figure 2C). Thus, 18/20 assayed
metabolites behave according to our working hypothesis.
If we jointly consider the novel antiproliferative com-
pounds presented in this work and those metabolites
whose anticancer activity in Jurkat cells was previously
known (discussed above), the fraction of anticancer
metabolites among the compounds predicted to be low-
ered in Jurkat cells [(9+2)/104 = 0.106] is considerably
higher than that corresponding to the rest of the com-
pounds [(1+2+10+0)/(78+800) = 0.015]. A Fisher's exact
test indicates that the positive association between low-
ered metabolite levels in Jurkat cells as predicted by
Effect of endogenous metabolites on the proliferation of Jurkat cells Figure 2
Effect of endogenous metabolites on the proliferation of Jurkat cells. The percentage of surviving cells is given as a 
percentage of the number of control cells after 72 h of incubation in the presence of the tested metabolite at a concentration 
of 100 μmol/L. Effect of metabolites predicted to be lowered (A), increased (B) or unchanged (C) in Jurkat cells when com-
pared with normal lymphoblasts, on the proliferation of Jurkat cells (2 biological replicates, each with 4 analytical replicates). 
MQ = menaquinone; HS = α-hydroxystearic acid; DE = dehydroepiandrosterone; SU = 3-sulfino-L-alanine; DM = 5,6-dimethyl-
benzimidazole; SE = seleno-L-methionine; RB = riboflavin; TN = tryptamine; HA = hydroxyacetone; BR = bilirubin; AT = 
androsterone; HV = homovanillic acid; VA = vanillylmandelic acid; AA = N-acetyl-L-aspartate; TA = taurocholic acid, CA = cit-
ric acid; PA = pantothenic acid; GA = β-D-galactose; FA = folic acid; CH = cholesterol. Error bars represent standard error of 
mean.
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CoMet and antiproliferative activity of the metabolite in
that cell line is highly significant (two-tailed p-value = 8.7
× 10-6). These findings clearly support our hypothesis
regarding the active role of endogenous metabolites in
cancer, especially the concept that the metabolism of can-
cer cells may be regulated so that the intracellular concen-
tration of certain antiproliferative metabolites is reduced,
resulting in uninhibited cellular growth.
The growth inhibitory effects of some of the predicted
compounds may seem relatively low and the tested con-
centrations of 50 and 100 μmol/L too high compared
with most anticancer drugs of synthetic or natural origin.
However, this range of concentrations is not unreasonable
for metabolic compounds, since many metabolites can be
found at similar levels in the cytosol and/or extracellular
fluids [34]. Furthermore, when the effect of selected
metabolites on growth inhibition was tested in Jurkat and
lymphoblast cells cultured in identical conditions, a pat-
tern of selectivity of the antiproliferative effect towards the
cancer cell line became evident (Table 2). In an extreme
case, dehydroepiandrosterone at a concentration of 50
μM inhibited the growth of Jurkat cells but stimulated the
proliferation of lymphoblasts. Interestingly, several of our
newly found antiproliferative metabolites exhibited syn-
ergistic interactions consistent with the Systems Biology
approach of our method: the prediction was performed
on the entire metabolome and not on individual metabo-
lites or pathways. This raises the intriguing question of
what the result would be if concentrations close to those
observed in the normal cells could be achieved in the can-
cer cell for most metabolites, i.e. a reversion to a normal-
like metabolic profile, at least for metabolites that inhibit
cancer cell growth. If the antiproliferative activities we
observed in a cancer cell line have therapeutic value, dif-
ferent combined strategies can be devised where sets of
predicted metabolites are concurrently selected according
to their association with the same or different metabolic
pathways. For example, we can employ a strategy where
multiple metabolites target a single pathway, or on the
contrary, where each metabolite acts specifically on a dif-
ferent pathway. In addition, some active metabolites
might serve as completely novel lead compounds for fur-
ther drug design and development, with the advantage of
reduced initial toxicity. While we have only performed
cell proliferation assays, it is reasonable to speculate that
some metabolites may also exhibit anti-metastatic (anti-
invasive), anti-angiogenic, immunostimulant or other
anticancer properties that would not be evident in an in
vitro study of cell growth inhibition.
We did not investigate here the mode of action of the anti-
proliferative metabolites found by CoMet, and it is possi-
ble that some may exert their effect based on completely
novel mechanisms, whose elucidation goes well beyond
the immediate scope of this study. However, for most, we
can suggest a possible mode of action based on their effect
on other cancer cells or on the known properties of closely
related molecules. For example, 5,6-dichlorobenzimida-
zole, a bioisosteric derivative of the active metabolite 5,6-
dimethylbenzimidazole, induces differentiation of malig-
nant erythroblasts by inhibiting RNA polymerase II [35].
The tested metabolite tryptamine is an effective inhibitor
of HeLa cell growth via the competitive inhibition of tryp-
tophanyl-tRNA synthetase, and consequent inhibition of
protein biosynthesis [36]. 9-hydroxystearic acid, an iso-
mer of the active metabolite α-hydroxystearic acid, arrests
HT29 colon cancer cells in G0/G1 phase of the cell cycle
via overexpression of p21 [37], induces differentiation of
HT29 cells [38] by inhibition of histone deacetylase 1 [39]
and interrupts the transduction of the mitogenic signal
[40]. Menaquinone (vitamin K2), the most efficient com-
pound among the tested metabolites, has been previously
reported to induce G0/G1 arrest, differentiation and
apoptosis in acute myelomonocytic leukemia HL-60 cells
[41].
Table 2: Differential effect of selected metabolites on the growth of Jurkat cells and normal lymphoblasts
Jurkat Lymphoblasts
Metabolite c [μM]1 Growth [%] SEM [%]2 p-value Growth [%] SEM [%]2 p-value
Menaquinone 100 18.2 0.36 4.5 × 10-7 89.7 8.5 0.38
50 40.3 1.15 2.0 × 10-7 109.9 5.8 0.23
Dehydroepiandrosterone 100 23.8 0.18 2.1 × 10-6 94.9 0.6 0.15
50 83.2 0.23 2.0 × 10-3 130.8 6.9 0.020
Se-Seleno-L-methionine 100 41.0 0.67 1.0 × 10-7 79.3 5.8 0.028
50 53.2 0.85 2.0 × 10-3 84.2 1.4 2.7 × 10-4
5,6-dimethylbenzimidazole 100 80.4 3.56 6.2 × 10-3 82.9 4.4 0.023
50 87.8 1.41 0.021 97.4 1.9 0.037
1 Metabolite concentration.
2 Standard error of the mean.
3 Statistical significance of the observed effect on cell growth, as evaluated by two-tailed t-tests.Molecular Cancer 2008, 7:57 http://www.molecular-cancer.com/content/7/1/57
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Caveats and possible improvements of the approach
Besides the general problems that affect any microarray
study [42,43], there are some factors not accounted in our
method that can influence the actual intracellular levels of
a metabolite. First, our qualitative treatment of metabolic
flux is highly simplified; however, more quantitative
approaches such as flux balance analysis require the
knowledge of the regulatory effects of covalent modifica-
tions and the kinetic rate constants of the associated
enzymes, information that is both incomplete and not
accurate enough to generate large-scale models [44]. Sec-
ond, the information available about both the subcellular
location where the metabolic conversions take place and
the transport of metabolites between different intra- or
extracellular compartments is very limited. To partially
address this issue, we are currently incorporating informa-
tion about transporter genes into CoMet for qualitative
metabolic flux predictions. Finally, a factor that could
confound the hypothetical correlation between lowered
metabolites in cancer and their potential as therapeutic
agents is the existence of moonlighting activities, such as
transcriptional regulation and apoptosis, exhibited by sev-
eral metabolic enzymes [45]. Since the growth control
functions of moonlighting enzymes do not involve catal-
ysis, their regulated levels in cancer cells may not be cor-
related with the intracellular concentration of their
metabolic substrates or products. Nevertheless, in spite of
these in principle limitations, in practice, CoMet greatly
succeeded in identifying antiproliferative metabolites. On
the other hand, its ability to predict changes in intracellu-
lar metabolite concentrations still needs to be proven by
experimentally determining the relative intracellular lev-
els of a representative set of metabolites in normal and
cancer cells, a task that we are planning to carry out in the
near future.
Conclusion
By applying CoMet, a Systems Biology based method for
Computational Metabolomics, we have discovered eleven
metabolites that either alone or in combination exhibit
significant antiproliferative activity in Jurkat cells. The
rationale behind our findings can be described by a sim-
ple premise: we posited that some metabolites that have
lowered levels in a cancer cell as compared to normal cells
might contribute to the progress of the disease. Our results
strongly suggest that many other metabolites with impor-
tant roles in cellular growth control may be waiting to be
discovered, opening up the possibility of novel
approaches against cancer. While traditionally cancer has
been viewed as involving gene regulation, control and sig-
naling processes that are disconnected from metabolism,
in reality such processes are not disjoint; i.e., the cell is an
integrated machine where such processes are likely to be
highly coupled in many instances. CoMet adopts this
viewpoint, and the resulting simple hypothesis that
inspired its creation can greatly assist in the understand-
ing of the contribution of metabolism to this complex dis-
ease.
Methods
Biological Databases
The main source of biological information is the Kyoto
Encyclopedia of Genes and Genomes (KEGG) from July 5,
2007 [46]. We obtained the enzyme function annotation
for human genes from the KEGG GENES database, the
chemical information about human metabolites from the
KEGG LIGAND database, and the metabolic pathway data
from the KEGG PATHWAY database. Enzyme function
annotations from KEGG were complemented by high
confidence predictions made by EFICAz [47], our highly
precise approach for enzyme function inference that sig-
nificantly increases annotation coverage [48]. For the
mapping between microarray probe identifiers and Entrez
GeneID identifiers, the Affymetrix HG-U133 Plus 2.0
NetAffx Annotation file of May 31, 2007 was used [49].
Gene expression status for enzyme-coding genes
The first step of the CoMet approach consists of the classi-
fication of each enzyme-coding human gene into four
possible groups: G1) upregulated in cancer cells, G2)
downregulated in cancer cells, G3) expressed in both, nor-
mal and cancer cells, at levels that are statistically indistin-
guishable, and G4) not expressed in both, normal and
cancer cells. We used two types of data for the classifica-
tion: the log base 2 signal intensities and the presence calls
of the corresponding probe sets, as reported by the
Affymetrix Microarray Suite Software 5.0 (MAS 5.0). First,
an "off" status is assigned to each gene in each of the two
studied conditions (normal and cancer) if the mean frac-
tion of presence calls labeled as "marginal" or "absent" in
the corresponding probe sets is at least 80%; otherwise, an
"on" status is assigned. Then, each gene is classified into
the G1, G2, G3 or G4 group, according to its on/off status
in normal and cancer conditions and the following crite-
rion for differential expression: the signal intensities in
normal and cancer samples exhibit a statistically signifi-
cant difference in at least 40% of the corresponding probe
sets, as evaluated by an ANOVA two-tailed test with P <
0.005.
Generation of genetic-metabolic matrix
The second step is the in silico estimation of the effect that
the differentially expressed enzyme-encoding genes may
exert on the intracellular levels of metabolites. First, all
human metabolic pathways from the KEGG PATHWAY
database, a compilation of maps representing the molec-
ular interactions and reaction networks for different types
of biological processes, were retrieved. For biological
process labeled as Metabolism, there are eleven groups of
pathways: 1) Carbohydrate Metabolism, 2) Energy Metab-Molecular Cancer 2008, 7:57 http://www.molecular-cancer.com/content/7/1/57
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olism, 3) Lipid Metabolism, 4) Nucleotide Metabolism,
5) Amino Acid Metabolism, 6) Metabolism of Other
Amino Acids, 7) Glycan Biosynthesis and Metabolism, 8)
Biosynthesis of Polyketides and Nonribosomal Peptides,
9) Metabolism of Cofactors and Vitamins, 10) Biosynthe-
sis of Secondary Metabolites, and 11) Xenobiotics Biodeg-
radation and Metabolism. The pathway maps are
available as graphical images and also as KEGG Markup
Language (KGML) files that facilitate the parsing of rele-
vant biological data. We extracted all the biochemical
reactions from the KGML human metabolic pathway
maps, including information about substrates, products,
direction/reversibility and associated enzyme-coding
genes. We then combined this information with gene
expression data from normal and cancer cells to construct
a genetic-metabolic matrix that links each of 1,477 metab-
olites with the specific human genes encoding for
enzymes that consume and/or produce each metabolite,
storing for each gene the differential expression status
given by the four-group classification described in the pre-
vious section.
From the genetic-metabolic matrix, we excluded: i) 209
non-physiological metabolites, here defined as those that
only participate in reactions that belong to the "Biosyn-
thesis of Secondary Metabolites" and the "Xenobiotics
Biodegradation and Metabolism" groups of metabolic
pathways, e.g. ecgonine or parathion, ii) 90 metabolites
that are considered ubiquitous and often carry out generic
roles in many reactions [50], here defined as those that are
involved as substrate or product in 20 or more reactions,
e.g. H2O, ATP, NAD(+)(P) or O2, and iii) 289 metabolites
that participate in reactions that are mainly catalyzed by
orphan human enzymes. We define the number of reac-
tions where a metabolite m acts as substrate or product in
human metabolic pathways as Nrm, human, and in reference
(non organism specific) metabolic pathways as Nrm, ref. If
Nrm, human/Nrm, ref < 0.5, then the metabolite m belongs to
the third exclusion category. The reactions absent in
human pathways may be due to orphan enzymes, reac-
tions that only occur in other organisms or reactions that
may occur in humans but have not yet been detected. For
example, the metabolite 1-alkyl-sn-glycero-3-phosphate
is excluded because out of four enzymes that use it as sub-
strate or product, two, EC 2.3.1.105 and EC 1.1.1.101, are
orphans in human, and one, EC 2.7.1.93, has only been
found in rabbit [51]. The total number of metabolites
remaining in the genetic-metabolic matrix after the three
types of exclusion is 982 (see Additional File 2).
Scanning of genetic-metabolic matrix
In the last step, we apply a simple set of rules to scan the
genetic-metabolic matrix for metabolites whose intracel-
lular levels in cancer cells are likely to differ from those in
normal cells. The rules are based on the supposition that
lower levels of enzymes catalyzing the production of a
metabolite (or higher levels of enzymes catalyzing the
consumption of it) imply decreased level of such metabo-
lite, and vice versa (see Figure 1). In our methodology, a
given metabolite is predicted to have decreased levels in
cancer cells when: 1) both of the following apply: 1.1)
there is no gene encoding for an enzyme able to catalyze
the production of the metabolite whose differential
expression status is G1 (upregulated in cancer cells) or G3
(significantly expressed at similar levels in normal and
cancer cells) and 1.2) there is no gene encoding for an
enzyme able to catalyze the consumption of the metabo-
lite whose differential expression status is G2 (downregu-
lated in cancer cells), and 2) either or both of the
following applies: 2.1) there is at least one gene encoding
for an enzyme able to catalyze the production of the
metabolite whose differential expression status is G2
(downregulated in cancer cells) and 2.2) there is at least
one gene encoding for an enzyme able to catalyze the con-
sumption of the metabolite whose differential expression
status is G1 (upregulated in cancer cells). Similarly, a
metabolite is predicted to have increased levels in cancer
cells when: 1) both of the following applies: 1.1) there is
no gene encoding for an enzyme able to catalyze the con-
sumption of the metabolite whose differential expression
status is G1 or G3 and 1.2) there is no gene encoding for
an enzyme able to catalyze the production of the metabo-
lite whose differential expression status is G2, and 2)
either or both of the following applies: 2.1) there is at least
one gene encoding for an enzyme able to catalyze the con-
sumption of the metabolite whose differential expression
status is G2 and 2.2) there is at least one gene encoding for
an enzyme able to catalyze the production of the metabo-
lite whose differential expression status is G1. Thus, the
methodology attempts to consider, as much as is practical,
the entire proteome complement of enzymes that pro-
duce and consume the metabolite. That is, our approach
is Systems Biology based.
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